Print

PPD, Inc. (PPDI) Launches New Clinical Trials Mobile Application  
3/29/2011 9:21:06 AM

WILMINGTON, N.C., (March 28, 2011) - PPD, Inc. (Nasdaq: PPDI) today announced it has launched its new Clinical Trials Mobile application for use on Apple® iPad™ and Apple® iPhone™ devices to help potential clinical research participants and investigators find clinical trials across a wide range of therapeutic areas.

The application provides quick and advanced keyword search menus, allowing users to search the U.S. National Library of Medicine ClinicalTrials.gov database of more than 100,000 global clinical trials. Users can customize their search by location, gender, age and other search criteria. The application gives users details about specific trials such as eligibility criteria, trial locations and contact information. Trial searches can be saved for future reference and detailed trial information can be sent via email.

In addition, investigators and potential U.S.-based clinical trial participants can register in PPD's ClinicalTrials.com database to be alerted as new clinical trials become available that meet their specific criteria.

"Mobile devices have become important tools for potential patients and investigators in their search for clinical trials targeted toward a specific disease," said Mike Wilkinson, Ph.D., executive vice president and chief information officer for PPD. "PPD is focused on delivering new technologies that educate these groups about the opportunities available to them and making the search for finding clinical trials an easier, more efficient process."

PPD's Clinical Trials Mobile application is available for download free of charge at the Apple® iTunes™ store by searching "PPD." PPD will demo the application at the 20th Annual Partnerships in Clinical Trials Conference being held 30 March-1 April in Phoenix. Participants can stop by PPD Booth No. 601 for a demonstration.

PPD is a leading global contract research organization providing drug discovery, development and lifecycle management services. Our clients and partners include pharmaceutical, biotechnology, medical device, academic and government organizations. With offices in 44 countries and more than 11,000 professionals worldwide, PPD applies innovative technologies, therapeutic expertise and a commitment to quality to help clients and partners accelerate the delivery of safe and effective therapeutics and maximize the returns on their R&D investments. For more information, visit www.ppdi.com. Except for historical information, all of the statements, expectations and assumptions contained in this news release, including expectations and assumptions about PPD's Clinical Trials Mobile application, are forward-looking statements that involve a number of risks and uncertainties. Although PPD attempts to be accurate in making these forward-looking statements, it is possible that future circumstances might differ from the assumptions on which such statements are based. In addition, other important factors which could cause results to differ materially include the following: rapid technological advances that make our products and services less competitive; competition within the outsourcing industry; risks associated with acquisitions and investments, such as impairments; continued success in sales growth; loss of or delay in large contracts; increased cancellation rates; economic conditions and outsourcing trends in the pharmaceutical, biotechnology, medical device, academic and government industry segments; the ability to attract and retain key personnel; risks associated with and dependence on collaborative relationships; and the other risk factors set forth from time to time in the SEC filings for PPD, copies of which are available free of charge upon request from the PPD investor relations department.

Contacts

Media: Sue Ann Pentecost +919 456 5890 sueann.pentecost@ppdi.com

Analysts/Investors:

Luke Heagle +910 558 7585 luke.heagle@ppdi.com


//-->